Champions Oncology, Inc. (CSBR) Q1 2027 Earnings Call

Investor webinar replay

Replay transcript excerpt

Speaker 1: Welcome to the Champions Oncology 1st 0.25 fiscal year 2027 Speaker 1: earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. Speaker 1: If anyone should require operator assistance during the conference, please press star 0 on your telephone keypad. Please note this conference is being recorded. Speaker 1: I will now turn the conference over to your host, Rob Brannon, Chief Executive Officer. You may begin. Speaker 2: Good afternoon, and Thank you for joining our 1st 0.25 fiscal 2027 earnings call. I'm Rob Brannon, CEO of Champion Fontology, and I'm joined today by our CFO, David Miller. Speaker 2: Before we begin, I'll remind everyone that today's remarks may include forward-looking statements. Speaker 2: Actual results may differ materially, and you can find more information in our filings with the SEC. Speaker 2: When we spoke in July, I said fiscal 26 was an investment year and that the onus was on us to deliver in fiscal 2027. Speaker 2: The 1st 0.25 is a strong data point that we're moving in the right direction. Speaker 2: That view was 15.2 million compared to 14 million in the 1st 0.25 of fiscal 26. Speaker 2: Gross margin was 50%, Speaker 2: up from 43% Speaker 2: in Q1 fiscal 26. Speaker 2: Adjusted EBITDA was approximately $700, 000, Speaker 2: And on a gap basis, we reported a net loss of .4 million. That included 1.1 million of non-cash expense. Speaker 2: This represents our 5th consecutive 0.25 of positive adjusted EBITDA. Speaker 2: Both our services business and our data business contributed to that improvement, and I'll touch on them in turn. Speaker 2: Our translational oncology Speaker 2: services business generated 14.3 million in revenue in the 0.25...